LILRB2 and non-small cell lung carcinoma: Chen et al., for example, found that inhibition of the immunoglobulin-like transcript 4 (ILT4) could prevent TAM-mediated immunosuppression and improve the efficacy of treatment with a PD-L1 inhibitor in NSCLC patients with EGFR mutation (96).